Here's Why uniQure Is Rallying 13% Today
After big biopharma Astellas (OTC: ALPMY) (OTC: ALPMF) agreed to acquire clinical-stage gene therapy company Audentes Therapeutics (NASDAQ: BOLD) for $3 billion in cash, uniQure's (NASDAQ: QURE) shares have jumped 13% at 12:15 pm EDT on Tuesday.
Although Audentes and uniQure are researching treatments for different indications, both companies are attempting to develop new solutions for genetic disorders by tinkering with genetic code.
Image source: Getty Images.
Source Fool.com
